目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 5 REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 7 CONTRAST MEDIA INDUSTRY: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT

3 EXECUTIVE SUMMARY (Page No. - 41)
FIGURE 9 CONTRAST MEDIA MARKET, BY TYPE, 2023 VS. 2029 (USD BILLION)
FIGURE 10 CONTRAST MEDIA INDUSTRY, BY FORM, 2023 VS. 2029 (USD BILLION)
FIGURE 11 MARKET, BY MODALITY, 2023 VS. 2029 (USD BILLION)
FIGURE 12 MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2029 (USD BILLION)
FIGURE 13 MARKET, BY INDICATION, 2023 VS. 2029 (USD BILLION)
FIGURE 14 MARKET, BY APPLICATION, 2023 VS. 2029 (USD BILLION)
FIGURE 15 MARKET, BY END USER, 2023 VS. 2029 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 46)
4.1 CONTRAST MEDIA MARKET OVERVIEW
FIGURE 17 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
4.2 NORTH AMERICA: CONTRAST MEDIA INDUSTRY, BY END USER & COUNTRY (2022)
FIGURE 18 HOSPITALS, CLINICS, & AMBULATORY SURGERY CENTERS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 MARKET: REGIONAL MIX
FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.4 MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA AND INDIA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 49)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CONTRAST MEDIA MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases
TABLE 2 CANCER INCIDENCE, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2020 VS. 2030 VS. 2040
5.2.1.2 Growing number of approvals of contrast media
5.2.1.3 Rising volume of CT and MRI examinations performed
TABLE 4 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019-2021
TABLE 5 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019-2021
5.2.1.4 Growing number of diagnostic centers and hospitals
5.2.1.5 Availability of reimbursement
5.2.1.6 Increasing demand for early disease diagnosis
5.2.1.7 Increasing funding by public-private organizations
TABLE 6 LIST OF BENEFICIARY HOSPITALS OF NHS WALES
5.2.2 RESTRAINTS
5.2.2.1 Side-effects and risks of allergic reactions associated with contrast media
TABLE 7 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA
5.2.3 OPPORTUNITIES
5.2.3.1 Generic contrast media
5.2.3.2 Increasing research on contrast media
TABLE 8 INDICATIVE LIST OF RESEARCH STUDIES
5.2.3.3 Growth opportunities in emerging economies
5.2.3.4 Increasing demand for minimally invasive imaging procedures
5.2.4 CHALLENGES
5.2.4.1 Preference for alternative modalities of imaging that do not require contrast media
5.2.4.2 Restriction of linear gadolinium-based contrast media and product recalls
5.2.4.3 Dearth of trained professionals
TABLE 9 US: METROPOLITAN AREAS WITH HIGH EMPLOYMENT LEVELS FOR RADIOLOGY TECHNOLOGISTS AND TECHNICIANS, 2022
5.2.4.4 Shortage of contrast media
5.3 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS: CONTRAST MEDIA INDUSTRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 24 SUPPLY CHAIN ANALYSIS: MARKET
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT OF SUBSTITUTES
5.7 REGULATORY LANDSCAPE
TABLE 10 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING MARKET
5.7.1 EU REGULATIONS
5.7.2 FDA REGULATIONS
5.7.3 JPMA REGULATIONS
5.8 PATENT ANALYSIS
FIGURE 25 PATENT ANALYSIS: IODINATED CONTRAST MEDIA
FIGURE 26 PATENT ANALYSIS: GADOLINIUM-BASED CONTRAST MEDIA
5.9 KEY CONFERENCES & EVENTS IN 2024-2025
TABLE 11 LIST OF CONFERENCES & EVENTS IN MARKET
5.10 PRICING ANALYSIS
TABLE 12 AVERAGE SELLING PRICE OF CONTRAST MEDIA
5.11 TRADE ANALYSIS
TABLE 13 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 14 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018-2022 (USD MILLION)
5.12 ECOSYSTEM ANALYSIS
FIGURE 27 ECOSYSTEM ANALYSIS: MARKET
TABLE 15 ROLE IN ECOSYSTEM
FIGURE 28 KEY PLAYERS OPERATING IN MARKET
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
5.14.2 BUYING CRITERIA
FIGURE 30 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 17 KEY BUYING CRITERIA FOR END USERS

6 CONTRAST MEDIA MARKET, BY TYPE (Page No. - 80)
6.1 INTRODUCTION
TABLE 18 CONTRAST MEDIA INDUSTRY, BY TYPE, 2021-2029 (USD MILLION)
6.2 IODINATED CONTRAST MEDIA
6.2.1 HIGH DEMAND FOR IODINATED CONTRAST MEDIA DUE TO HIGHER DOSAGE REQUIRED IN CT SCANS—KEY FACTOR DRIVING MARKET GROWTH
TABLE 19 MARKET, BY REGION, 2021-2029 (USD MILLION)
TABLE 20 MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
6.3 GADOLINIUM-BASED CONTRAST MEDIA
6.3.1 SUSPICION REGARDING SAFETY PROFILE TO CHALLENGE MARKET GROWTH
TABLE 21 MARKET, BY REGION, 2021-2029 (USD MILLION)
TABLE 22 MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
6.4 MICROBUBBLE CONTRAST MEDIA
6.4.1 EXTREMELY POPULAR AMONG PHYSICIANS WORLDWIDE
TABLE 23 MARKET, BY REGION, 2021-2029 (USD MILLION)
TABLE 24 MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
6.5 BARIUM-BASED CONTRAST MEDIA
6.5.1 ADVERSE EFFECTS ASSOCIATED WITH USE TO NEGATIVELY IMPACT MARKET
TABLE 25 MARKET, BY REGION, 2021-2029 (USD MILLION)
TABLE 26 MARKET, BY COUNTRY, 2021-2029 (USD MILLION)

7 CONTRAST MEDIA MARKET, BY FORM (Page No. - 90)
7.1 INTRODUCTION
TABLE 27 CONTRAST MEDIA INDUSTRY, BY FORM, 2021-2029 (USD MILLION)
7.2 LIQUID CONTRAST MEDIA
7.2.1 INCREASING ADOPTION OF EASY-TO-USE LIQUID FORM OF CONTRAST MEDIA ACROSS HOSPITALS AND DIAGNOSTIC CENTERS TO DRIVE MARKET
TABLE 28 MARKET, BY REGION, 2021-2029 (USD MILLION)
7.3 POWDER CONTRAST MEDIA
7.3.1 EASE OF HANDLING, STORAGE, AND TRANSPORTATION TO FAVOR ADOPTION
TABLE 29 MARKET, BY REGION, 2021-2029 (USD MILLION)
7.4 OTHER FORMS
TABLE 30 MARKET FOR OTHER FORMS, BY REGION, 2021-2029 (USD MILLION)

8 CONTRAST MEDIA MARKET, BY MODALITY (Page No. - 95)
8.1 INTRODUCTION
TABLE 31 NUMBER OF PROCEDURES PERFORMED, BY MODALITY, 2017-2020
TABLE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2021-2029 (MILLION LITERS)
TABLE 33 CONTRAST MEDIA INDUSTRY, BY MODALITY, 2021-2029 (USD MILLION)
8.2 X-RAY
8.2.1 PRODUCTION OF HIGH-QUALITY IMAGES TO DRIVE MARKET
TABLE 34 UK: NUMBER OF X-RAY TESTS PERFORMED, 2012-2020
TABLE 35 MARKET FOR X-RAY, BY REGION, 2021-2029 (USD MILLION)
TABLE 36 MARKET FOR X-RAY, BY COUNTRY, 2021-2029 (USD MILLION)
8.3 CT
8.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET
TABLE 37 NUMBER OF CT SCANNERS PER 1,000 INHABITANTS, BY COUNTRY, 2020 VS. 2021
TABLE 38 UK: NUMBER OF CT SCANS PERFORMED, 2012-2020
TABLE 39 MARKET FOR CT, BY REGION, 2021-2029 (USD MILLION)
TABLE 40 MARKET FOR CT, BY COUNTRY, 2021-2029 (USD MILLION)
8.4 MRI
8.4.1 ADVANTAGES OF MRI OVER OTHER IMAGING MODALITIES TO SUPPORT MARKET GROWTH
TABLE 41 NUMBER OF MRI UNITS PER 1,000 INHABITANTS, BY COUNTRY, 2019 VS. 2020 VS. 2021
TABLE 42 UK: NUMBER OF MRI TESTS PERFORMED, 2012-2020
TABLE 43 MARKET FOR MRI, BY REGION, 2021-2029 (USD MILLION)
TABLE 44 MARKET FOR MRI, BY COUNTRY, 2021-2029 (USD MILLION)
8.5 ULTRASOUND
8.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY-KEY FACTORS DRIVING MARKET GROWTH
TABLE 45 UK: NUMBER OF ULTRASOUND TESTS PERFORMED, 2012-2020
TABLE 46 MARKET FOR ULTRASOUND, BY REGION, 2021-2029 (USD MILLION)
TABLE 47 MARKET FOR ULTRASOUND, BY COUNTRY, 2021-2029 (USD MILLION)

9 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 108)
9.1 INTRODUCTION
TABLE 48 CONTRAST MEDIA INDUSTRY, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
9.2 INTRAVASCULAR ROUTE
9.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTE IN IMAGING MODALITIES TO DRIVE MARKET
9.2.1.1 Intravenous (IV) route
9.2.1.2 Intra-arterial (IA) route
TABLE 49 MARKET FOR INTRAVASCULAR ROUTE, BY REGION, 2021-2029 (USD MILLION)
TABLE 50 MARKET FOR INTRAVASCULAR ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
9.3 ORAL ROUTE
9.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN GIT, LEADING TO PERITONITIS
TABLE 51 MARKET FOR ORAL ROUTE, BY REGION, 2021-2029 (USD MILLION)
TABLE 52 MARKET FOR ORAL ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
9.4 RECTAL ROUTE
9.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH
TABLE 53 MARKET FOR RECTAL ROUTE, BY REGION, 2021-2029 (USD MILLION)
TABLE 54 MARKET FOR RECTAL ROUTE, BY COUNTRY, 2021-2029 (USD MILLION)
9.5 OTHER ROUTES
TABLE 55 MARKET FOR OTHER ROUTES, BY REGION, 2021-2029 (USD MILLION)
TABLE 56 MARKET FOR OTHER ROUTES, BY COUNTRY, 2021-2029 (USD MILLION)

10 CONTRAST MEDIA MARKET, BY INDICATION (Page No. - 117)
10.1 INTRODUCTION
TABLE 57 CONTRAST MEDIA INDUSTRY, BY INDICATION, 2021-2029 (USD MILLION)
10.2 CARDIOVASCULAR DISEASE
10.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET
TABLE 58 MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2029 (USD MILLION)
TABLE 59 MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2029 (USD MILLION)
10.3 CANCER
10.3.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO HIGH CANCER PREVALENCE IN REGION
TABLE 60 CANCER INCIDENCE, BY REGION, 2020 VS. 2035 (MILLION)
TABLE 61 MARKET FOR CANCER, BY REGION, 2021-2029 (USD MILLION)
TABLE 62 MARKET FOR CANCER, BY COUNTRY, 2021-2029 (USD MILLION)
10.4 GASTROINTESTINAL DISORDERS
10.4.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH
TABLE 63 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 64 MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
10.5 MUSCULOSKELETAL DISORDERS
10.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH
TABLE 65 MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 66 MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
10.6 NEUROLOGICAL DISORDERS
10.6.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET
TABLE 67 MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 68 MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
10.7 NEPHROLOGICAL DISORDERS
10.7.1 RISING PREVALENCE OF ESRD TO DRIVE DEMAND FOR DIAGNOSTIC TOOLS
TABLE 69 MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 70 MARKET FOR NEPHROLOGICAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)

11 CONTRAST MEDIA MARKET, BY APPLICATION (Page No. - 130)
11.1 INTRODUCTION
TABLE 71 CONTRAST MEDIA INDUSTRY, BY APPLICATION, 2021-2029 (USD MILLION)
11.2 RADIOLOGY
11.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET
TABLE 72 MARKET FOR RADIOLOGY, BY REGION, 2021-2029 (USD MILLION)
TABLE 73 MARKET FOR RADIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
11.3 INTERVENTIONAL RADIOLOGY
11.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH
TABLE 74 MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2021-2029 (USD MILLION)
TABLE 75 MARKET FOR INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
11.4 INTERVENTIONAL CARDIOLOGY
11.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET
TABLE 76 MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2021-2029 (USD MILLION)
TABLE 77 MARKET FOR INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)

12 CONTRAST MEDIA MARKET, BY END USER (Page No. - 138)
12.1 INTRODUCTION
TABLE 78 CONTRAST MEDIA INDUSTRY, BY END USER, 2021-2029 (USD MILLION)
12.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS
12.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET
TABLE 79 MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 80 MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021-2029 (USD MILLION)
12.3 DIAGNOSTIC IMAGING CENTERS
12.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET
TABLE 81 MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021-2029 (USD MILLION)
TABLE 82 MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021-2029 (USD MILLION)

13 CONTRAST MEDIA MARKET, BY REGION (Page No. - 144)
13.1 INTRODUCTION
TABLE 83 CONTRAST MEDIA INDUSTRY, BY REGION, 2021-2029 (USD MILLION)
13.2 NORTH AMERICA
FIGURE 31 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT
TABLE 84 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET, BY FORM, 2021-2029 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 91 NORTH AMERICA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.2.1 US
13.2.1.1 Rising incidence of chronic diseases to drive market
TABLE 92 US: KEY MACROINDICATORS
TABLE 93 US: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 94 US: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 95 US: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 96 US: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 97 US: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 98 US: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.2.2 CANADA
13.2.2.1 Increasing investments in improving medical imaging to drive market
TABLE 99 CANADA: KEY MACROINDICATORS
TABLE 100 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 101 CANADA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 102 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 103 CANADA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 104 CANADA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 105 CANADA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.2.3 RECESSION IMPACT ON NORTH AMERICAN MARKET
13.3 EUROPE
TABLE 106 EUROPE: NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, BY COUNTRY, 2021
TABLE 107 EUROPE: NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, BY COUNTRY, 2021
TABLE 108 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
TABLE 109 EUROPE: MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 110 EUROPE: MARKET, BY FORM, 2021-2029 (USD MILLION)
TABLE 111 EUROPE: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 112 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 113 EUROPE: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 114 EUROPE: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 115 EUROPE: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.1 GERMANY
13.3.1.1 Presence of well-developed diagnostic imaging infrastructure to support market growth
TABLE 116 GERMANY: KEY MACROINDICATORS
TABLE 117 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 118 GERMANY: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 119 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 120 GERMANY: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 121 GERMANY: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 122 GERMANY: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.2 FRANCE
13.3.2.1 Increasing prevalence of cancer to propel market
TABLE 123 FRANCE: KEY MACROINDICATORS
TABLE 124 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 125 FRANCE: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 126 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 127 FRANCE: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 128 FRANCE: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 129 FRANCE: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.3 UK
13.3.3.1 Increasing investments in diagnostic imaging to boost market growth
TABLE 130 UK: KEY MACROINDICATORS
TABLE 131 UK: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 132 UK: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 133 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 134 UK: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 135 UK: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 136 UK: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.4 ITALY13.3.4.1 Rising geriatric population to drive demand for diagnostic procedures
TABLE 137 ITALY: KEY MACROINDICATORS
TABLE 138 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 139 ITALY: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 140 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 141 ITALY: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 142 ITALY: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 143 ITALY: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.5 SPAIN
13.3.5.1 Shortage of radiologists to restrain market growth
TABLE 144 SPAIN: KEY MACROINDICATORS
TABLE 145 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 146 SPAIN: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 147 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 148 SPAIN: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 149 SPAIN: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 150 SPAIN: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.6 REST OF EUROPE
TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2021 VS. 2022
TABLE 152 REST OF EUROPE: NUMBER OF MRI AND CT UNITS AND SCANS, BY COUNTRY, 2021
TABLE 153 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 154 REST OF EUROPE: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 155 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 156 REST OF EUROPE: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 157 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 158 REST OF EUROPE: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.3.7 RECESSION IMPACT ON EUROPEAN MARKET
13.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT
TABLE 159 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
TABLE 160 ASIA PACIFIC: MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: MARKET, BY FORM, 2021-2029 (USD MILLION)
TABLE 162 ASIA PACIFIC: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 163 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 165 ASIA PACIFIC: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 166 ASIA PACIFIC: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.1 CHINA
13.4.1.1 High incidence of cancer and stroke to support market growth
TABLE 167 CHINA: KEY MACROINDICATORS
TABLE 168 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 169 CHINA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 170 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 171 CHINA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 172 CHINA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 173 CHINA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.2 JAPAN
13.4.2.1 Strong healthcare sector and high disease incidence to favor market growth
TABLE 174 JAPAN: KEY MACROINDICATORS
TABLE 175 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 176 JAPAN: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 177 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 178 JAPAN: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 179 JAPAN: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 180 JAPAN: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.3 INDIA
13.4.3.1 Growing investments in radiology to propel market growth
TABLE 181 INDIA: KEY MACROINDICATORS
TABLE 182 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 183 INDIA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 184 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 185 INDIA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 186 INDIA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 187 INDIA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.4 AUSTRALIA
13.4.4.1 Increasing research activities to drive market
TABLE 188 AUSTRALIA: KEY MACROINDICATORS
TABLE 189 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 190 AUSTRALIA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 191 AUSTRALIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 192 AUSTRALIA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 193 AUSTRALIA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 194 AUSTRALIA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.5 REST OF ASIA PACIFIC
TABLE 195 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, BY COUNTRY, 2021
TABLE 196 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 198 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 199 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 200 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 201 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.4.6 RECESSION IMPACT ON ASIA PACIFIC MARKET
13.5 REST OF THE WORLD
TABLE 202 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY REGION, 2021-2029 (USD MILLION)
TABLE 203 REST OF THE WORLD: MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 204 REST OF THE WORLD: MARKET, BY FORM, 2021-2029 (USD MILLION)
TABLE 205 REST OF THE WORLD: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 206 REST OF THE WORLD: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 207 REST OF THE WORLD: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 208 REST OF THE WORLD: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 209 REST OF THE WORLD: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.5.1 LATIN AMERICA
13.5.1.1 Lack of adequate healthcare infrastructure and poor insurance coverage to limit market growth
TABLE 210 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 211 LATIN AMERICA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 212 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 213 LATIN AMERICA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 214 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 215 LATIN AMERICA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.5.2 MIDDLE EAST & AFRICA
13.5.2.1 High burden of chronic diseases to drive market
TABLE 216 ISRAEL: DIAGNOSTIC IMAGING DATA, 2022
TABLE 217 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 220 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 222 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.5.3 GCC COUNTRIES
13.5.3.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market
TABLE 223 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE, 2021-2029 (USD MILLION)
TABLE 224 GCC COUNTRIES: MARKET, BY MODALITY, 2021-2029 (USD MILLION)
TABLE 225 GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2029 (USD MILLION)
TABLE 226 GCC COUNTRIES: MARKET, BY INDICATION, 2021-2029 (USD MILLION)
TABLE 227 GCC COUNTRIES: MARKET, BY APPLICATION, 2021-2029 (USD MILLION
TABLE 228 GCC COUNTRIES: MARKET, BY END USER, 2021-2029 (USD MILLION)
13.5.4 RECESSION IMPACT ON REST OF THE WORLD MARKET

14 COMPETITIVE LANDSCAPE (Page No. - 218)
14.1 OVERVIEW
14.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 229 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET
14.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA INDUSTRY
14.4 MARKET SHARE ANALYSIS
TABLE 230 CONTRAST MEDIA INDUSTRY: DEGREE OF COMPETITION
FIGURE 34 CONTRAST MEDIA INDUSTRY SHARE, BY KEY PLAYER (2022)
14.5 COMPANY EVALUATION MATRIX
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
FIGURE 35 CONTRAST MEDIA INDUSTRY: COMPANY EVALUATION MATRIX, 2022
14.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 231 FOOTPRINT ANALYSIS
TABLE 232 TYPE FOOTPRINT
TABLE 233 REGIONAL FOOTPRINT
14.6 STARTUP/SME EVALUATION MATRIX
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
FIGURE 36 CONTRAST MEDIA INDUSTRY: STARTUP/SME EVALUATION MATRIX, 2022
14.7 COMPETITIVE BENCHMARKING
TABLE 234 CONTRAST MEDIA MARKET: KEY STARTUPS/SMES
14.8 COMPETITIVE SCENARIO
14.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 235 CONTRAST MEDIA INDUSTRY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020-DECEMBER 2023
14.8.2 DEALS
TABLE 236 CONTRAST MEDIA INDUSTRY: DEALS, JANUARY 2020-DECEMBER 2023
14.8.3 OTHER DEVELOPMENTS
TABLE 237 CONTRAST MEDIA INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020-DECEMBER 2023
14.9 BRAND/PRODUCT COMPARISON: CONTRAST MEDIA MARKET
TABLE 238 BRAND/PRODUCT COMPARISON (IODINATED CONTRAST MEDIA)
TABLE 239 BRAND/PRODUCT COMPARISON (GADOLINIUM-BASED CONTRAST MEDIA)

15 COMPANY PROFILES (Page No. - 232)
(Business overview, Products offered, Recent developments & MnM View)*
15.1 KEY PLAYERS
15.1.1 GE HEALTHCARE
TABLE 240 GE HEALTHCARE: BUSINESS OVERVIEW
FIGURE 37 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
15.1.2 BRACCO IMAGING SPA
TABLE 241 BRACCO IMAGING SPA: BUSINESS OVERVIEW
15.1.3 BAYER AG
TABLE 242 BAYER AG: BUSINESS OVERVIEW
FIGURE 38 BAYER AG: COMPANY SNAPSHOT (2022)
15.1.4 GUERBET
TABLE 243 GUERBET: BUSINESS OVERVIEW
FIGURE 39 GUERBET: COMPANY SNAPSHOT (2022)
15.1.5 LANTHEUS MEDICAL IMAGING
TABLE 244 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW
FIGURE 40 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2022)
15.1.6 UNIJULES LIFE SCIENCES LTD.
TABLE 245 UNIJULES LIFE SCIENCES LTD.: BUSINESS OVERVIEW
15.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED
TABLE 246 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: BUSINESS OVERVIEW
FIGURE 41 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)
15.1.8 SANOCHEMIA PHARMAZEUTIKA
TABLE 247 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW
15.1.9 TAEJOON PHARM CO., LTD.
TABLE 248 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW
15.1.10 JODAS EXPOIM
TABLE 249 JODAS EXPOIM: BUSINESS OVERVIEW
15.1.11 IMAX DIAGNOSTIC IMAGING LIMITED
TABLE 250 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW
15.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP
TABLE 251 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW
15.1.13 LIVEALTH BIOPHARMA
TABLE 252 LIVEALTH BIOPHARMA PVT. LTD.: BUSINESS OVERVIEW
15.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD.
TABLE 253 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
15.2 OTHER PLAYERS
15.2.1 UNISPIRE BIOPHARMA PRIVATE LIMITED
15.2.2 ARCO LIFESCIENCES (I) PVT. LTD.
15.2.3 STANEX DRUGS & CHEMICALS PVT. LTD.
15.2.4 REGE IMAGING & CINE FILMS PRIVATE LIMITED
15.2.5 K DIAM EXIM
15.2.6 ONKO ILAÇ SAN. VE TIC. A.S.
15.2.7 FRESENIUS KABI
15.2.8 BIEM ILAÇ SAN. VE TIC. A.S.
15.2.9 ADVACARE PHARMA

16 APPENDIX (Page No. - 270)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS